Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Sutro Biopharma Inc. currently manages 8 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 6 distinct art units, indicating a diverse range of subject matter within the life sciences sector. The involvement of 7 distinct examiners suggests that the company must navigate varied examination styles and requirements simultaneously.
The busiest examiner for this portfolio is HUYNH, PHUONG N, who is responsible for 2 of the pending office actions. This concentration represents a specific point of focus for the company's legal strategy, as the other actions are spread among the remaining examiners. Managing 8 total actions across 7 examiners requires a broad approach to prosecution, as most examiners are handling only a limited number of matters for the company at this time.
The presence of these pending office actions highlights the active nature of the company's patent acquisition efforts. Practitioners should note that while HUYNH, PHUONG N handles 2 actions, the overall distribution remains relatively decentralized across the 7 distinct examiners involved. The 6 distinct art units in play further underscore the technical breadth of the pending applications.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (14%) |
| §112 only | 3 (43%) |
| Double-patenting + other | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KAUFMAN, CLAIRE M | 1 | 63.5% | +50.7% |
| REGLAS, GEORGIANA C | 1 | 37.7% | +36.1% |
| HOWARD, ZACHARY C | 1 | 64.0% | +37.9% |
| GALSTER, SAMUEL LEONARD | 1 | 50.9% | +43.2% |
| HUYNH, PHUONG N | 1 | 65.7% | +53.6% |
| RYAN, DOUGLAS CHARLES | 1 | 39.2% | +47.6% |
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16991607 | EXPRESSION OF BIOLOGICALLY ACTIVE PROTEINS IN A BACTERIAL CELL-FREE SYNTHESIS SYSTEM USING BACTERIAL CELLS TRANSFORMED TO EXHIBIT ELEVATED LEVELS OF CHAPERONE EXPRESSION | RYAN, DOUGLAS CHARLES | 18d overdue |
| 17727395 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | HUYNH, PHUONG N | 2d overdue |
| 16395649 | HIGH GROWTH CAPACITY AUXOTROPHIC ESCHERICHIA COLI AND METHODS OF USE | PERSONS, JENNA L | 6d |
| 18638420 | ANTI-BCMA ANTIBODIES AND TREATMENT METHODS | KAUFMAN, CLAIRE M | 15d |
| 18231204 | SPRAY DRIED EXTRACT | REGLAS, GEORGIANA C | 22d |
| 18357956 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | HOWARD, ZACHARY C | — |
| 18215093 | BETA-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF | GALSTER, SAMUEL LEONARD | — |
| Art Unit | Apps |
|---|---|
| 1674 | 2 |
| 1651 | 1 |
| 1693 | 1 |
| 1641 | 1 |
| 1635 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18638420 | ANTI-BCMA ANTIBODIES AND TREATMENT METHODS | KAUFMAN, CLAIRE M | 1674 | §112 | Non-Final OA | 15d | Pending | Apr 17, 2024 |
| 18231204 | SPRAY DRIED EXTRACT | REGLAS, GEORGIANA C | 1651 | §103 | Final Rejection | 22d | Pending | Aug 07, 2023 |
| 18357956 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | HOWARD, ZACHARY C | 1674 | §112Other | Non-Final OA | — | Pending | Jul 24, 2023 |
| 18215093 | BETA-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF | GALSTER, SAMUEL LEONARD | 1693 | §103DP | Non-Final OA | — | Pending | Jun 27, 2023 |
| 17727395 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | HUYNH, PHUONG N | 1641 | §112Other | Final Rejection | 2d overdue | Pending | Apr 22, 2022 |
| 16991607 | EXPRESSION OF BIOLOGICALLY ACTIVE PROTEINS IN A BACTERIAL CELL-FREE SYNTHESIS SYSTEM USING BACTERIAL CELLS TRANSFORMED TO EXHIBIT ELEVATED LEVELS OF CHAPERONE EXPRESSION | RYAN, DOUGLAS CHARLES | 1635 | §103§112DP | Final Rejection | 18d overdue | Pending | Aug 12, 2020 |
| 16395649 | HIGH GROWTH CAPACITY AUXOTROPHIC ESCHERICHIA COLI AND METHODS OF USE | PERSONS, JENNA L | 1637 | §103DP | Final Rejection | 6d | Pending | Apr 26, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial